CompletedNot Applicable

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

United States62 participantsStarted 2023-10-06

Plain-language summary

The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device. Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 50 years or older and may be either male or female and may be of any race * Established diagnosis of GA due to AMD * GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation * Willing to participate as evidenced by signing the written informed consent Exclusion Criteria: * Unable to tolerate opthalmic imaging * Presence of neovascular AMD on OCT as confirmed by an ophthalmologist * Presence of significant media opacity preventing adequate retinal imaging * Presence of concurrent retinal disease which may confound assessment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This study compared different retinal imaging systems for measuring geographic atrophy — does my eye care team currently use the Heidelberg Spectralis, the Zeiss Clarus 700, or the Optos California, and does it matter which one is used to track my condition over time?
2Since this trial found that some imaging systems showed more than a 10% difference in geographic atrophy area measurements compared to the Heidelberg Spectralis, could switching between imaging devices at different appointments make my disease progression look different than it actually is?
3This was a completed observational study comparing imaging tools rather than testing a treatment — does it change how you would monitor my geographic atrophy, or does it affect which imaging system you'd recommend for my follow-up care?
4Given that the accuracy of measuring geographic atrophy size matters for tracking how fast my condition is progressing, should I ask that my future scans always be done on the same type of machine to keep my results consistent?
5Are there any implications from this study's findings that would affect my eligibility or monitoring if I were to consider enrolling in a treatment trial for geographic atrophy in the future?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Comparison of Geographic Atrophy Area Measurements With Heidelberg Spectralis to Zeiss Clarus 700 and Optos California

Timeframe: Up to 75 minutes

Comparison of Geographic Atrophy Area Measurements With Heidelberg Spectralis to Zeiss Clarus 700 and Optos California (Full Range Reported)

Timeframe: Up to 75 minutes

Number of Eyes With Greater Than 10% Difference in Geographic Atrophy Area Than Heidelberg RegionFinder

Timeframe: up to 75 mintues

Trial details

NCT IDNCT05961332

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-27

Results submitted2026-05-18

View on ClinicalTrials.gov More Macular Degeneration, Age Related trials

Plain-language summary

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Comparison of Geographic Atrophy Area Measurements With Heidelberg Spectralis to Zeiss Clarus 700 and Optos California

Timeframe: Up to 75 minutes

Comparison of Geographic Atrophy Area Measurements With Heidelberg Spectralis to Zeiss Clarus 700 and Optos California (Full Range Reported)

Timeframe: Up to 75 minutes

Number of Eyes With Greater Than 10% Difference in Geographic Atrophy Area Than Heidelberg RegionFinder

Timeframe: up to 75 mintues